Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis

Reuters

06-03

Chemomab <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis $(PSC.AU)$, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540934779"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540934779\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540934779?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540934779","market":"us","top_or_hot":-1,"title":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMMB\">Chemomab Therapeutics Ltd.</a> has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis <a href=\"https://laohu8.com/S/PSC.AU\">$(PSC.AU)$</a>, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-03 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMMB\">Chemomab Therapeutics Ltd.</a> has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis <a href=\"https://laohu8.com/S/PSC.AU\">$(PSC.AU)$</a>, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2vkPky:1","article_id":"2540934779","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540934779","pubTimestamp":1748952049,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis. Chemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis , with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","CMMB":"Chemomab Therapeutics Ltd.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Chemomab Therapeutics在中国和俄罗斯获得Nebokitug新专利，巩固其在治疗原发性硬化性胆管炎方面的地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMMB":0.9,"NDAQ":0.9},"content_text":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n    \n\nChemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis $(PSC.AU)$, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}